anthonyyazdaniml/gliner-biomed-balanced-curated-corpus huggingface dataset:
PURPOSE: To obtain a polyether polymer excellent in hue and useful as e.g. a starting material for cosmetics by bringing a polyether polymer derived from a polyepihalohydrin into contact with a specified compound. CONSTITUTION: Nitrogenous groups are introduced into a polyepihalohydrin comprising repeating units of formula I (wherein V is a halogen; and m has an average of 10-1,500) to obtain a polyether polymer comprising repeating units represented by formula II [wherein Y is a group of formula III or IV (wherein R&lt;1&gt; and R&lt;2&gt; are each a 1-20C (hydroxy) alkyl or alkenyl; and Z is a 1-20C (hydroxy) alkylene)] and bringing this polymer into contact with a boron hydride compound. The decolorization reaction of the polymer with the boron hydride compound is carried out in a solution. The solvents used are desriably alcohols and water, particularly desirably water. The boron hydride compound is particularly desirably sodium boron hydride.
The invention relates to the technical field of medicines, in particular to a tea bag for treating xerophthalmia, which is prepared from the following raw material medicines in parts by weight: 2 parts of radix pseudostellariae, 2 parts of dendrobium, 1 part of adenophora tetraphylla, 2 parts of wolfberry fruit, 2 parts of radix ophiopogonis, 1 part of butterflybush flower, 2 parts of albizzia julibrissin and 3 parts of cicada fungus. The invention also comprises the application of the bulk drug in the preparation of the medicine for treating xerophthalmia and the preparation method of the tea bag for treating xerophthalmia. Its advantages are: 1. the selected raw material medicines have wide sources, all the raw material medicines accord with the compatibility principle of &#39;monarch, minister, assistant and guide&#39;, and the traditional Chinese medicine is safe and has no toxic or side effect. 2. The invention adopts a targeted therapy to treat patients, and the experimental result proves that: the treatment efficiency is high, the patient acceptance is high, and the recurrence rate is low. 3. The proportion of the traditional Chinese medicine components is screened by tests, and the effect is obvious. 4. The preparation method is simple and convenient in preparation process, has exact curative effect on xerophthalmia patients, and has good application prospect.
&lt;P&gt;PROBLEM TO BE SOLVED: To safely and easily ionize metal, which is a metal element, through a simple device.  &lt;P&gt;SOLUTION: The selected Figure shows an embodiment in which generated gold ions are used for facial treatment. Extremely fine mist containing gamma polyglutamic acid is sprayed onto a gold foil 11. The extremely fine mist containing the gamma polyglutamic acid is produced by projecting ultrasonic waves into a liquid containing gamma polyglutamic acid. By spraying the extremely fine mist containing gamma polyglutamic acid onto the gold foil 11, gold is ionized and enters the skin receiving the facial treatment and is easily absorbed.  &lt;P&gt;COPYRIGHT: (C)2010,JPO&amp;INPIT
Methods, systems, and computer-readable media are provided for aggregating, partitioning, and storing healthcare data. Healthcare data is collected from various disparate healthcare data sources. The data is aggregated into batches of the same type of data. From here, the data is partitioned according to the data&#39;s originating healthcare data source. The aggregated and partitioned healthcare data is then stored in a long term storage data store. This system of storing healthcare data allows for efficient retrieval and processing by computing solutions that need access to batches of healthcare data. The system also reduces costs associated with storing data as duplicate storage is eliminated.
PURPOSE:To produce a cosmetic having excellent moisture-retention, feeling to the skin and make-up durability by compounding flaky silk fibroin powder with a mucopolysaccharide to improve the moisture-retention of the silk fibroin powder and compounding the produced composite powder having excellent feeling to a cosmetic base. CONSTITUTION:This silk fibroin powder compounded with a mucopolysaccharide is produced by adding an aqueous solution of silk fibroin to an aqueous solution of a mucopolysaccharide or its salt, thoroughly mixing the mixture, freeze-drying the obtained dispersion, subjecting the resultant dried material (silk fibroin containing mucopolysaccharide uniformly dispersed and occluded in the silk fibroin) to wet-heat treatment with saturated steam of &gt;=80 deg.C to effect the denaturation of the silk fibroin and obtain a partially crosslinked silk fibroin insoluble in hot water (beta-type structure) and crushing the denaturated product to a prescribed size by a crusher such as a hammer mill. A cosmetic is prepared by compounding the powder (preferably flaky powder). The amount of the mucopolysaccharide or its salt in the cosmetic is preferably 0.01-20 pts.wt. based on 100 pts.wt. of the silk fibroin powder compounded with the mucopolysaccharide.
PURPOSE:To provide a prostaglandin E1 (PGE1) fat emulsion containing PGE1, an oil base, a phospholipid and water, free from higher fatty acid as an emulsifying assistant and having remarkably improved storage stability of PGE1. CONSTITUTION:The objective PGE1 fat emulsion contains (A) PGE1, (B) an oil base such as a vegetable oil (e.g. soybean oil or sesame oil) especially having a purity of &gt;=98%, preferably &gt;=99.8% as a glyceride, (C) a phospholipid, e.g. a refined phospholipid such as yolk lecithin or soybean lecithin and (D) water and is free from a higher fatty acid (e.g. oleic acid) or its salt as an emulsifying assistant. The amounts of the components A and B are 0.0001-0.001W/V% and 5-50W/V%, respectively, and the weight ratio of C/B is 1/100 to 1/2. The emulsion may be further incorporated with an emulsion stabilizer other than higher fatty acid and its salt, a polymeric substance, an isotonizing agent, an antioxidant, etc.
1,139,869. Multilayer tablets. MOORE MEDICINAL PRODUCTS Ltd. 6 Jan., 1967 [6 Jan., 1966], No. 707/66. Heading A5B. A multilayer tablet comprises one layer formed from a mixture of a water-soluble drug and a pharmaceutically acceptable waterabsorbent substance which forms one or more stable hydrates (e.g. citric acid or its Na or K salt, or the Na or K salt of tartaric or phosphoric acid), but which is&#39;-present in a fully or partially dehydrated form, the other layer or layers present not being water-absorbent. The other layer, or one of the other layers present may contain a water-insoluble drug. The acids or salts may initially be admixed with the drug in dehydrated form or they may be dehydrated by the action of heat during the preparation of the admixture for the tabletting operation. The example relates to a tablet with a core consisting of sucrose, methylephedrine hydrochloride, theophylline hydrate and magnesium stearate coated with a composition of gelatin, sucrose, talc, isoprenaline sulphate, antioxidants, citric acid and colouring agents. The tablets of the invention ensure that a water-soluble drug is retained in the desired location in the tablet. Enteric coatings may be used where desired.
The invention belongs to the field of biochemistry, and particularly relates to an RNA inhibitor for inhibiting hepatitis B virus gene expression and application thereof. The RNA inhibitor is formed by a positive-sense strand and an antisense strand through base pairing, and at least 85% of bases between the positive-sense strand and the antisense strand are complementary; -OH at the 2&#39;site of partial or all nucleotide glycosyls is substituted by fluorine or methoxyl, and phosphate among at least three continuous nucleotides at the tail end is sulfated. The structure of the RNA inhibitor also contains 5&#39;MVIP and 3&#39;MVIP, so that the RNA inhibitor has specific liver targeting. The RNA inhibitor provided by the invention has the efficacy which is not possessed by the current clinical first-line hepatitis B treatment medicine, and can continuously and efficiently inhibit the synthesis of HBV surface antigen HBsAg and the generation of surface antibody HBsAb. The RNA inhibitor disclosed by the invention has a remarkable inhibition effect on the most common A, B, C and D types of HBV. The RNA inhibitor is combined with a nucleoside analogue or interferon for use, so that the hepatitis B can be functionally cured.
&lt;P&gt;PROBLEM TO BE SOLVED: To obtain an external preparation for skin containing one or more kinds of skin elasticity ameliorants selected from active ingredients for providing the skin with firmness and moisture, especially a cosmetic which has excellent feels (elasticity, emollient feeling, spread and moisture retaining property) in use and improved stability with time, especially a massage cream.  &lt;P&gt;SOLUTION: The external preparation for skin contains one or more kinds of skin elasticity ameliorants selected from active ingredients which have no adverse effect, are stable and safe and provide the skin with firmness and moisture. The skin care preparation contains the skin elasticity ameliorant and/or one or more kinds of essential components. The external preparation for skin provides a cosmetic which has excellent feels (elasticity, emollient feeling, spread and moisture retaining property) in use and improved stability with time, especially a massage cosmetic. The cosmetic is widely useful in various technical fields such as medicines, foods, etc., not to mention the field of cosmetic and has excellent effect of achieving the purpose of the invention.  &lt;P&gt;COPYRIGHT: (C)2004,JPO
PURPOSE:To obtain the titled pharmaceutical preparation useful for skin diseases such as Behcet&#39;s disease, necrotic blood inflammation, etc., capable of being administered endermically without causing side effect, by forming a high polymer substance layer consisting of a high polymer substance pressure-sensitive at normal temperature and colchicine on a substrate. CONSTITUTION:An effective amount of colchicine is added to a high polymer substance pressure-sensitive at normal temperature, preferably (meth)acrylate high polymer substance [e.g., (meth)acrylic acid butyl ester, (meth)acrylic acid pentyl ester, etc.] in such a way that colchicine is dispersed uniformly or in high content at the surface layer part, and a high polymer substance layer is formed on a flexible substrate (e.g., cloth, plastic film, etc.), to give the titled pharmaceutical preparation. Colchicine administration is quantitatively carried out with a sufficient ODT effect, a partial concentration can be effectively raised, and diseases can be effectively remedied while lowering side effects. Colchicine is preferably adjusted to 1-500mug strength/cm&lt;2&gt;.
PURPOSE:An agent against mutagenesis for deactivating mutagenesis of carcinostatic substance, containing phyridoxal-5&#39;-phosphate, a vitamin B complex component of type present in vivo, as an active ingredient. CONSTITUTION:An agent against mutagenesis containing pyridoxal phosphate such as a compound shown by the formula I as an active ingredient. The compound shown by the formula I inhibits about 50wt% mutagenesis of N-methyl-N&#39;- nitro-N-nitroguanidine, a carcinogenic substance in the stomach and the intestine when 150 times as much the compound shown by the formula I as the nitroguanidine by molar amount is used. It deactivates about 80wt% benz [a]pyrene a carcinogenic substance in the liver and the skin, when 25 times as much the compound as benz [a]pyrene by molar amount is used. Namely, pyridoxal-5&#39;- phosphate is found to be effective for preventing carcinogenesis as an agent for mutagenesis. Vitamin B6 shown by the formula II is a type present in vivo, safe, has effects as vitamin, and is usable in the field of drug, food, or table luxuries.
Methods and devices provide physiological movement detection with active sound generation. In some versions, a processor may detect breathing and/or gross body motion. The processor may control producing, via a speaker coupled to the processor, a sound signal in a user&#39;s vicinity. The processor may control sensing, via a microphone coupled to the processor, a reflected sound signal. This reflected sound signal is a reflection of the sound signal from the user. The processor may process the reflected sound, such as by a demodulation technique. The processor may detect breathing from the processed reflected sound signal. The sound signal may be produced as a series of tone pairs in a frame of slots or as a phase-continuous repeated waveform having changing frequencies (e.g., triangular or ramp sawtooth). Evaluation of detected movement information may determine sleep states or scoring, fatigue indications, subject recognition, chronic disease monitoring/prediction, and other output parameters.
&lt;P&gt;PROBLEM TO BE SOLVED: To obtain a highly safe and readily producible gel composition optimal when utilized as a base for a cosmetic, a medicine, or the like, having high strengths and good stretchability, stable even in use over a long period, and to provide a method for producing the same.  &lt;P&gt;SOLUTION: The gel composition is obtained by heating a mixture containing natural polysaccharides containing at least uronic acid and a deoxysaccharide in a constituent monosaccharide, a polyhydric alcohol and water and has the stretchability. The method for producing the same is provided. Polysaccharides produced by a microorganism can be used as the natural polysaccharides, e.g. the polysaccharides produced by a bacterium Alcaligenes latus B-16 strain. Acidic polysaccharides containing glucose, fucose, glucuronic acid and rhamnose as constituent monosaccharides can be used as the polysaccharides.  &lt;P&gt;COPYRIGHT: (C)2005,JPO&amp;NCIPI
The present invention relates to a tonic medicated wine, particularly to a medicated wine which is prepared by taking Chinese herbal medicines as raw materials. Aiming at the condition that a tonic medicated wine can not be drunk generally when a person catches wind cold and common cold at present, the medicated wine of the present invention is especially prepared. The medicated wine is prepared in a way that a deer&#39;s kidney, a donkey&#39;s kidney, a dog&#39;s kidney, glossy ganoderma, eucommia bark, cordyceps, pinenut kernel, scorpio, semen cassiae torae, safflowers, longan pulp, chrysanthemum flowers, gastrodia tubers, medlar, tremella, camptotheca acuminata, goldhair hedyotis herbs, etc. are soaked with wine and are sealed in a cellar. The medicated wine contains 18 kinds of amino acids and microelements, and can activate blood, benefit qi, nourish stomachs, promote the production of the body fluid and resist hypoxia, aging and viruses. The present invention has the advantage of good mouth feel and is suitable for people with any physical status.
&lt;P&gt;PROBLEM TO BE SOLVED: To provide a method for producing a mixture of antibodies from a single host cell clone.  &lt;P&gt;SOLUTION: The invention provides the methods for producing mixtures of antibodies from a single host cell clone. Additionally, a nucleic acid sequence encoding a light chain, and nucleic acid sequences encoding different heavy chains are expressed in a recombinant host cell. The antibodies in the mixtures suitably comprise identical light chains paired to different heavy chains pairing to the light chain, thereby forming functional antigen binding domains. The mixtures of antibodies are also provided. Such mixtures can be used in a variety of fields.  &lt;P&gt;COPYRIGHT: (C)2011,JPO&amp;INPIT
FIELD: biotechnology, genetic engineering, molecular biology. SUBSTANCE: recombinant plasmid DNA has human cytomegalovirus gene UL 32 fragment that encodes the total hydrophilic site (3 antigenic epitopes) of basic matrix phosphoprotein pp 150 and 3&#39;-end located DNA fragment that encodes polyhistidine tract used for purification of protein by affinity chromatography method. Structure provides effective biosynthesis of polypeptide. Obtained recombinant polypeptide shows antigenic properties of human cytomegalo-virus. The use of this antigen in immunoenzyme assay for detection of cytomegalovirus-specific immunoglobulins in patient blood shows 98-99% of sensitivity and specificity for IgG-human cytomegalovirus and 80-90% for IgM-human cytomegalo-virus. EFFECT: valuable antigenic properties of antigen. 4 dwg, 2 ex
&lt;P&gt;PROBLEM TO BE SOLVED: To provide a container for oxidation dye capable of preventing any inter-layer peeling from being produced among many resin layers constituting a container wall even if the stored articles are stored for a long period of time under their storage state.  &lt;P&gt;SOLUTION: This container for oxidation dye is composed of multi-layer structure made of synthetic resin. This container is used for storing stored contents including oxidation dye, in particular stored contents containing 14 or more-carbon number fatty alcohol and/or hydrocarbon-based fats and oils (paraffin classification, ester classification). The multi-layer structure is constituted to have an oxygen barrier layer, a moisture barrier layer positioned inside the oxygen barrier layer and an anti-contents barrier layer positioned inside the moisture barrier layer. Content-proof barrier plies or layers preferably consist of polyamide-based resin.  &lt;P&gt;COPYRIGHT: (C)2006,JPO&amp;NCIPI
PROBLEM TO BE SOLVED: To obtain a new nitrone compound useful as an antioxidant and useful as a treating agent capable of fighting to congestive disease, etc., relating to cerebral senescence and fighting to not only acute nerval denaturation disease such as ischemia but also neuron death relating to progressive nerval denaturation disease such as Alzheimer&#39;s disease. SOLUTION: This nitrone compound is expressed by formula I [W is a (substituted) aryl or the like; R1 is a 1-6C alkyl or the like; R2 is H, a 1-6C alkyl or the like], preferably (z)-α-(2-phenyl-1H-imidazol-4-yl)-N-tert-butylnitrone. The compound of formula I is obtained by e.g. treating a compound of formula II (e.g. 2-phenyl-4-trifluoromethyl-1H-imidazole) with ammonium hydroxide and subjecting to hydrolysis, subjecting to reducing reaction to obtain a compound of formula III, then treating the resultant compound with a compound of the formula: HO-NHR1 (e.g. N-tert-butylhydroxylamine), as preferable one producing method.
&lt;P&gt;PROBLEM TO BE SOLVED: To provide a technique for improving the adhesiveness-maintaining property of a coating film formed on a skin in a water-in-oil emulsion type powder-containing external preparation for the skin.  &lt;P&gt;SOLUTION: This water-in-oil emulsion type powder-containing external preparation for the skins is characterized by containing a powder having an N-acylamino acid salt-containing coating layer in an amount of 5 to 50 mass%. The N-acylamino acid salt is preferably aluminum N-lauroyl glutamate and/or aluminum N-stearoyl glutamate. It is preferable to contain an organic-modified clay mineral as an emulsifying component. In addition, it is preferable that an acryl-silicone-based graft copolymer and 12-hydroxystearic acid are contained.  &lt;P&gt;COPYRIGHT: (C)2009,JPO&amp;INPIT
Objectionable flavours are removed from fatty oils containing vitamin A, its esters, alcohol or any provitamin A, by passing the oil in solution in a non-polar saturated hydrocarbon or mixture of such hydrocarbons through a column of anhydrous activated gamma alumina free from adsorbed water, and then separating the solvent from the resulting bland - tasting oil.  The anhydrous gamma alumina may be obtained by heating a crystalline aluminium tri-hydrate to above 500 DEG  C., the actual temperature and time of heating being insufficient to form the inert a -alumina.  A suitably activated gamma alumina may be found by testing the products obtained at various temperatures above 500 DEG  C. over various periods of heating, by measuring the absorptive capacity of the aluminas for a dye, waxoline blue being exemplified.  The weight of dye in milligrams adsorbed by 1 gram of the alumina may thus be obtained and a preferred product is one having an adsorptive capacity for waxoline blue of between 4.5 and 7.0 mgm. per gram of alumina.  The ratio of the weight of the alumina to the treated oil may be such that the concentration of vitamin in the oil is unchanged by the treatment, a ratio of 3 to 1 being preferred; the ratio may be sufficiently high to give a concentration of the vitamin in the oil, such as a ratio of 10 to 1.  The column of gamma alumina may be revivified by washing with a volatile solvent such as alcohol, followed by heating with hot air, externally applied steam &amp;c. to remove the solvent.  The gamma alumina may be re-activated by heating it to a temperature above 500 DEG  C.  The treated oils specified comprise shark liver oil, dogfish liver oil, whale liver oil, and palm oil containing carotene which is rich in provitamin A.  The non-polar saturated hydrocarbon solvents or mixtures thereof specified comprise petroleum ether, benzene and cyclohexane.
A plurality of remote terminals (A) are each disposed in a physician&#39;s office and are connected by telephone lines or other electronic data communication with a central processing system (B). Each terminal includes a data entry key board (10) and a magnetic tape reader (12) for entering physician, patient, medical service, insurance, and other medically related data. The entered data is processed by a terminal processor (20) to incorporate previously stored data from an electronic data memory and to transfer and store entered medical transaction data to memory. The central processing system includes a physician file for storing participating physician identifications for verifying received physician information data, a patient memory for storing participating patient data for verifying received patient identification data, an insurance company file for storing appropriate format for medical claims for each of a plurality of participating insurance companies, and a claims file for storing a record of medical insurance claims processed. A central processing computer processes the received data and formats it into the approriate format for a medical claim to the identified insurance company. A printer (D) or an electronic data transfer (C) transfers the medical claims from the central processing system directly to the insurance companies. Electronic funds transfer facilities at the central processing station and at one or more banks or financial institutions are called upon to transfer funds directly to a physician&#39;s account and to acknowledge receipt of funds from insurance company accounts.
This invention provides a method for determining whether an agent causes a reduction in the expression of a retromer complex protein. This invention further provides a method for determining whether an agent causes a reduction in the activity of a retromer complex. This invention also provides a method for reducing the expression of a retromer complex protein in a cell. This invention provides a method for treating a subject afflicted with Alzheimer&#39;s disease. This invention further provides a pharmaceutical composition as well as an article of manufacture. Finally, this invention provides a method for identifying a potential pathogenic nucleic acid transcript with respect to a brain disorder.